Thursday 16 October, 2025
Background: Raltegravir (RAL) pharmacokinetics (PK) exhibit large inter and intra-individual variability. The aims of the study were to (1) quantify…
Read morePoster: Infection
Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies
Thursday 16 October, 2025
Objectives: The study objective was to derive reference pharmacokinetic curves of antiretroviral drugs (ART) based on available population pharmacokinetic (Pop-PK)…
Read moreApplications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572)
Thursday 16 October, 2025
Objectives: Population pharmacokinetic (PK) analysis performed in early and late stages of clinical development generally serves different purposes. Population PK…
Read moreComparison of NONMEM and Pmetrics Analysis for Aminoglycosides in Adult Patients with Cystic Fibrosis
Thursday 16 October, 2025
Objectives: The aim of this study was to compare the performance of parametric and nonparametric approaches in population pharmacokinetic analysis…
Read moreDevelopment of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis
Thursday 16 October, 2025
Objectives: A tobramycin dose of 10 mg/kg every 24 hours is recommended for patients with cystic fibrosis. However, there is…
Read moreA population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria
Thursday 16 October, 2025
Objectives: Pregnancy has been associated with an increased risk of contracting a malaria infection and with higher risk of severe…
Read morePopulation Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults
Thursday 16 October, 2025
Objectives: Lopinavir is an antiretroviral drug administered with ritonavir to enhance its exposure. Rifampicin, a key component of antitubercular treatment,…
Read moreModel-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin
Thursday 16 October, 2025
Objectives: Doubling the dose of lopinavir/ritonavir has been shown to compensate for the induction effect of rifampicin in adults, but…
Read moreOptimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment
Thursday 16 October, 2025
Objectives: The objective was to explore different dosage regimens of ciprofloxacin for the treatment of Intensive Care Unit (ICU) patients…
Read moreModelling of protozoa dynamics and drug effects in a murine model of malaria infection
Thursday 16 October, 2025
Objectives: In humans, severe malaria is responsible of over a million of deaths every year. The development of new antimalarial…
Read more